EirGen Pharma

EirGen Pharma Focuses on Development, Registration, and Commercial Manufacturing of Highly Potent, High Barrier Solid Dose Products for the Global Pharmaceutical Market. EirGen Pharma is Fully Licensed to Produce Oncology, Cytotoxic, Steroidal, and Immunosuppressant Molecules in a Specially Built High-Containment Facility. The Existing Technical Facility Can Also Handle the Development of Humidity-Sensitive Molecules in a Low Humidity Environment. The Company Holds an Investigational Medicinal Product (IMP) License for Manufacturing Clinical Trial Materials and a Manufacturing License for Commercial Manufacturing and Packaging.